Schieferdecker H, Dilger H, Doerfel H, Rudolph W, Anton R
Health Phys. 1985 Jan;48(1):29-48. doi: 10.1097/00004032-198501000-00003.
Publication No. 30 of the International Commission on Radiological Protection (ICRP) assigns the uranium oxides UO2 and U3O8 to transportability class Y, i.e. the half-life of these compounds in the lungs is about 500 days. This assignment seemed not to be in accordance with our experience resulting from incorporation surveillance during UO2 fuel element fabrication. Persons who worked in atmospheres containing UO2 aerosols with activity concentrations significantly above the derived air concentrations (DAC) for class Y U showed much lower activity in the lungs than would be expected according to the ICRP. To understand this discrepancy, aerosol concentrations and aerosol particle-size distributions at work places with the possibility of UO2 incorporation, the activity of urine and feces and the lung activity of persons working at these places were measured in an investigation program. The results are only consistent with the ICRP lung model if one uses a measured biological half-life in the lungs of 109 days and a measured AMAD of 8.2 micron instead of the ICRP standard assumptions of 500 days and 1.0 micron, respectively. ICRP Publication No. 30 recommends application of specific parameters for health physics instead of standard model values. For the special conditions in our UO2 fuel fabrication plant we therefore derive limits of air concentrations, lung activities and fecal and urinary activity concentrations by applying our measured particle-size and lung-retention parameters to the ICRP model. Our special derived limits in comparison to class Y limits for U after ICRP Publication No. 30 for a 1-micron AMAD and 500-day half-life (in brackets) are: (a) annual limit of intake: 6 X 10(4) Bq/y (1 X 10(3) Bq/y); (b) derived air concentration: 20 Bq/m3 (0.6 Bq/m3); (c) derived lung activity: 1.6 X 10(3) Bq; (d) derived fecal activity: 14 Bq/day; and (e) derived urine activity: 8.9 Bq/day. The committed dose equivalents calculated from our measured data and from our modified derived limits proved consistent for the different incorporation control methods (determination of air concentration, lung, fecal or urinary activity). The authors recommend that in accordance with ICRP Publication No. 30, the national rules and regulations on activity incorporation provide the possibility to derive special limits from specific work-place parameters such as particle-size distributions and biological half-lives, thus supplementing the ICRP standard assumptions of 1 micron AMAD and biological half-lives of 0.5 days for class D, 50 days for class W and 500 days for class Y compounds.
国际放射防护委员会(ICRP)第30号出版物将氧化铀UO₂和U₃O₈归为可运输性Y类,即这些化合物在肺部的半衰期约为500天。这一归类似乎与我们在UO₂燃料元件制造过程中的摄入监测经验不符。在含有活性浓度显著高于Y类铀的导出空气浓度(DAC)的UO₂气溶胶的环境中工作的人员,其肺部的活性远低于ICRP预期的水平。为了解这种差异,在一项调查计划中,对可能摄入UO₂的工作场所的气溶胶浓度和气溶胶粒径分布、尿液和粪便的活性以及在这些场所工作的人员的肺部活性进行了测量。只有当使用在肺部测得的109天生物半衰期和测得的8.2微米的空气动力学等效直径(AMAD),而不是ICRP分别设定的500天和1.0微米的标准假设时,结果才与ICRP肺部模型一致。ICRP第30号出版物建议应用特定的健康物理学参数,而非标准模型值。因此,对于我们的UO₂燃料制造工厂的特殊情况,我们将测得的粒径和肺部滞留参数应用于ICRP模型,得出了空气浓度、肺部活性以及粪便和尿液活性浓度的限值。与ICRP第30号出版物发布后针对1微米AMAD和500天半衰期(括号内)的U的Y类限值相比,我们特殊推导的限值如下:(a)年摄入量限值:6×10⁴贝可勒尔/年(1×10³贝可勒尔/年);(b)导出空气浓度:20贝可勒尔/立方米(0.6贝可勒尔/立方米);(c)导出肺部活性:1.6×10³贝可勒尔;(d)导出粪便活性:14贝可勒尔/天;(e)导出尿液活性:8.9贝可勒尔/天。根据我们测得的数据和修改后的导出限值计算出的待积剂量当量,对于不同的摄入控制方法(空气浓度、肺部、粪便或尿液活性的测定)证明是一致的。作者建议,根据ICRP第30号出版物,关于活性摄入的国家法规应提供根据特定工作场所参数(如粒径分布和生物半衰期)推导特殊限值的可能性,从而补充ICRP对于D类化合物1微米AMAD和0.5天生物半衰期、W类化合物50天生物半衰期以及Y类化合物500天生物半衰期的标准假设。